2/28/2022 6:55:56 AM
Lexicon Voluntarily Withdraws Sotagliflozin NDA; Plans Prompt Resubmission Targeted Early Q2 2022
2/28/2022 6:18:12 AM
Lexicon Pharma Q4 Net Loss $25.6 Mln Or $0.17/Shr Vs Loss Of $5.5 Mln Or $0.04/Shr Last Year
1/14/2021 8:15:15 AM
Lexicon Gets FDA Feedback That Results Of SOLOIST, SCORED Phase 3 Studies Can Support NDA Submission
8/1/2019 10:10:16 AM
Wedbush Reiterates Lexicon Pharmaceuticals Inc. (LXRX) At Outperform With $17 Down From $35 Price Target
6/11/2019 12:57:20 PM
Wedbush Reiterates Lexicon Pharmaceuticals Inc. (LXRX) At Outperform With $35 Price Target
5/2/2019 8:56:18 AM
Wedbush Is Lowering Lexicon Pharmaceuticals Inc. (LXRX) FY20 Rev. Estimate To 98.2 M From 98.3 M
5/2/2019 8:56:06 AM
Wedbush Is Lowering Lexicon Pharmaceuticals Inc. (LXRX) FY19 Rev. Estimate To 63.8 M From 71.0 M
5/2/2019 8:55:49 AM
Wedbush Is Increasing Lexicon Pharmaceuticals Inc. (LXRX) Q4 19 Rev. Estimate To 19.5 M From 19.3 M
5/2/2019 8:55:18 AM
Wedbush Is Raising Lexicon Pharmaceuticals Inc. (LXRX) FY20 Estimate To -1.23 From -1.60
5/2/2019 8:55:04 AM
Wedbush Is Raising Lexicon Pharmaceuticals Inc. (LXRX) Q4 20 Estimate To -0.27 From -0.36
5/2/2019 8:54:50 AM
Wedbush Is Increasing Lexicon Pharmaceuticals Inc. (LXRX) Q3 20 Estimate To -0.30 From -0.39
5/2/2019 8:54:39 AM
Wedbush Is Increasing Lexicon Pharmaceuticals Inc. (LXRX) Q2 20 Estimate To -0.32 From -0.41
5/2/2019 8:54:26 AM
Wedbush Is Increasing Lexicon Pharmaceuticals Inc. (LXRX) Q1 20 Estimate To -0.35 From -0.43
5/2/2019 8:54:13 AM
Wedbush Is Raising Lexicon Pharmaceuticals Inc. (LXRX) FY19 Estimate To -0.77 From -0.95
5/2/2019 8:53:58 AM
Wedbush Is Raising Lexicon Pharmaceuticals Inc. (LXRX) Q4 19 Estimate To -0.22 From -0.30